A personalized cancer vaccine built from a patient’s own tumor just passed a Phase 3 trial.
The obvious question is: how much will it cost?
Early personalized cancer treatments like CAR-T can cost hundreds of thousands of dollars.
Sequencing has become dramatically cheaper. mRNA manufacturing has already proven it can scale. The remaining challenge is producing a treatment for one person at a time and that is fundamentally an automation problem.
The first version may be brutally expensive. That doesn’t mean the technology stays that way.
🔗 Watch the full video: https://youtu.be/Z9BJb8lS1lo
Credit to : Longevity Science News
Please Support our Sponsors here ---